reviewed april 2026|next review october 2026|88 physicians psi has verified|856 published studies
Livagen
Livagen is a synthetic tetrapeptide (lysyl-glutamyl-aspartyl-alanine) from the Khavinson bioregulatory medicine program, classified as a hepatic bioregulator with a notably higher human study count (61) than other Khavinson peptides.
Evidence landscape: 856 published studies
856 published items. 61 human studies and 105 animal studies.
- 61 Human
- 105 Animal
- 34 Reviews
- 656 Other research
Not FDA-approved. Not evaluated by any Western regulatory agency. Livagen is a research compound from the Khavinson bioregulatory program. The 61 human study count has not been independently characterized for quality and design.
Not available through Western pharmaceutical channels. Available through Russian supplement and research channels. Part of the Khavinson bioregulator series.
Livagen (Lys-Glu-Asp-Ala) is the hepatic bioregulator in the Khavinson organ-specific peptide series. It has the highest human study count (61) of any Khavinson bioregulator, suggesting relatively more clinical investigation than companion compounds. The proposed mechanism is chromatin decondensation in hepatocytes.
PSI Assessment
Among the Khavinson bioregulatory peptides, livagen stands out for one reason: 61 human studies, the highest count of any compound in the program. This tetrapeptide (Lys-Glu-Asp-Ala) is classified as the hepatic bioregulator, proposed to restore age-related liver function through chromatin remodeling in hepatocytes. The proposed mechanism is that livagen decondenses heterochromatin in liver cell nuclei, reactivating genes silenced during aging that are involved in detoxification capacity. Russian research reports chromatin structural changes. Independent replication outside the St. Petersburg Institute has not been published. What the 61 human studies specifically demonstrate in terms of study quality and design has not been independently characterized.
61 human studies, the highest count of any Khavinson bioregulator. A hepatic bioregulator proposed to restore age-related liver function through chromatin remodeling.
The proposed mechanism is chromatin decondensation in hepatocytes, restoring age-related gene expression changes that reduce liver detoxification capacity. Livagen (Lys-Glu-Asp-Ala) has the highest human study count (61) of any Khavinson bioregulator, suggesting relatively more clinical investigation than its companion compounds. Russian research reports that livagen modulates chromatin structure in liver cells, potentially restoring hepatic function during aging.
What the evidence supports
Russian research reports that livagen modulates chromatin condensation in hepatocytes. 61 human studies represent the highest clinical study count of any Khavinson bioregulator. The tetrapeptide structure (Lys-Glu-Asp-Ala) is characterized.
What is not yet established
Independent replication of chromatin remodeling findings outside the St. Petersburg Institute. Whether the reported hepatic effects translate to clinically meaningful liver function improvement. What the 61 human studies specifically demonstrate (study quality and design). Comparative efficacy against established hepatoprotective agents.
Research Evidence
The findings below cover livagen's proposed hepatic mechanism, the chromatin remodeling data, and the evidence context.
Evidence by condition
Evidence dimensions available for each condition Livagen has been studied for.
| Condition | Mechanism | Animal evidence | Human evidence | Replication |
|---|---|---|---|---|
| Liver Function | ||||
| Hepatic Aging | ||||
| Detoxification Capacity |
Russian research reports that livagen (Lys-Glu-Asp-Ala) modulates chromatin condensation in hepatocyte nuclei, with 61 human studies making it the most clinically investigated Khavinson bioregulator.
Independent replication of the chromatin remodeling findings has not been published. The quality and design of the 61 human studies has not been independently characterized.
61 Human|105 Animal|34 Reviews
View all 856 indexed studiesHow Livagen Works
Livagen (Lys-Glu-Asp-Ala) is a synthetic tetrapeptide from the Khavinson bioregulatory program. The proposed mechanism is chromatin decondensation in hepatocyte nuclei, reactivating age-suppressed genes involved in liver detoxification and regeneration. This mechanism has not been independently validated.
A four-amino-acid peptide from the Khavinson program proposed to support liver cell health by activating genes silenced during aging through chromatin remodeling.
For a more detailed view of the biology, here is what researchers have observed at the molecular level.
Lys-Glu-Asp-Ala tetrapeptide. Proposed chromatin decondensation in hepatocyte nuclei, reactivating age-suppressed genes involved in liver detoxification and regeneration.
What is Livagen being studied for?
Researchers are studying Livagen across several health conditions. Each condition below is labeled with the strength of evidence that exists for that specific use, not for Livagen overall. This means a compound can have human studies for one condition but only animal data for another.
Liver Function
·Animal StudiesRussian research reports that livagen modulates chromatin structure in hepatocytes. 61 human studies represent the highest clinical study count of any Khavinson bioregulator.
Limitations: Independent replication has not been published. The quality and design details of the 61 human studies have not been independently characterized.
Hepatic Aging
·Animal StudiesLivagen is proposed to restore age-related liver function decline through chromatin remodeling that reactivates genes involved in detoxification capacity.
Limitations: Whether chromatin remodeling translates to clinically meaningful liver function improvement is not established. All data from a single research program.
Detoxification Capacity
·PreclinicalThe proposed mechanism connects livagen to detoxification enzyme gene expression through chromatin decondensation in hepatocyte nuclei.
Limitations: The link between chromatin remodeling and clinically measurable detoxification capacity improvement is theoretical. No clinical assessment of detoxification outcomes has been published.
Safety and Regulatory Status
FDA Status: Not FDA-approved. Not evaluated by any Western regulatory agency. Research compound from the Khavinson program.
Availability: Not available through Western pharmaceutical channels. Available in Russia through supplement channels.
Class context: Livagen is a Khavinson bioregulator tetrapeptide (Lys-Glu-Asp-Ala). Published data suggests favorable tolerability. Tetrapeptide structure indicates low systemic toxicity risk.
Livagen has been used in Russian clinical practice with no significant reported safety concerns. As a simple tetrapeptide, toxicity risk is expected to be low. Independent Western safety assessment has not been conducted.
Peptide Structure
Technical molecular data for researchers and clinicians.
Questions and Comparisons
Questions the evidence raises for a Livagen discussion.
Comparison and Related Research
Livagen is the hepatic-targeted peptide in the Khavinson program. The comparisons below provide context against other hepatic and bioregulatory compounds.
Related compounds
Frequently Asked Questions
References
Each citation links to the original study on PubMed, the U.S. National Library of Medicine database.
- 1.A study demonstrating that livagen (KEDA tetrapeptide) activated heterochromatin in lymphocytes isolated from elderly human subjects. The research showed livagen-induced chromatin decondensation, which the authors proposed as a mechanism for restoring age-suppressed gene expression in immune cells.Khavinson VKh et al., 2002 in Bull Exp Biol Med. View on PubMed
- 2.An extension of the chromatin activation research, this study compared the effects of multiple short peptides, including livagen (KEDA), on lymphocyte chromatin structure in elderly subjects. The results showed that livagen specifically promoted chromatin remodeling in a pattern consistent with reactivation of silenced genes.Khavinson VKh et al., 2004 in Bull Exp Biol Med. View on PubMed
- 3.A systematic review cataloguing evidence for short peptide-DNA interactions across the Khavinson bioregulatory series. The review included livagen (KEDA) data and proposed that the tetrapeptide's chromatin-remodeling effects represent an epigenetic mechanism for hepatic gene regulation.Khavinson VK et al., 2021 in Molecules. View on PubMed
- 4.A study examining how livagen (KEDA) and polypeptide liver complex influenced physiological function in normal and age-related pathological conditions. The research evaluated hepatic function markers and proposed that livagen supports liver tissue homeostasis during aging.Kuznik BI et al., 2020 in Adv Gerontol. View on PubMed
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.